insulin icodec/semaglutide Icodec + Semaglutide (IcoSema / Kyinsu) A fixed-dose combination of: Basal insulin icodec (ultra-long acting) GLP-1 receptor agonist semaglutide Designed for once-weekly subcutaneous injection Current Status Completed Phase 3 trials (COMBINE Molecular and pharmacological characterization of

Both medications enhanced insulin secretion and reduced appetite, but tirzepatides dual action on GIP and GLP-1 pathways provides broader metabolic benefits including improved lipid profiles, blood pressure, and biomarkers of insulin sensitivity

Dose-dependent severity Side effects tend to track with dose level rather than which peptide is used, which is why both follow a slow titration schedule

doi: 10.1016/j.tplants.2020.01.004 15 DixonD

Pancreatitis: Anyone experiencing persistent severe abdominal pain, particularly if radiating to the back, should seek urgent medical attention, as this may indicate pancreatitis a recognised risk with incretin-based therapies

The Truth About "Happy Hour": Can You Drink on GLP-1s